by Eric Christianson | Jun 26, 2024 | Clinical Pharmacy News and New Drug Updates, Psychiatry and Addiction Medication and Disease State Clinical Pearls
I’ve encountered a significant proportion of patients who are on chronic benzodiazepines. Drug interactions, adverse effects, and other risks to my geriatric patient population are significant when using this class of medication. Benzodiazepine withdrawal is...
by Eric Christianson | May 12, 2024 | Clinical Pharmacy News and New Drug Updates, Gastrointestinal Medication and Disease State Clinical Pearls
On November 1, 2023, the U.S. Food and Drug Administration (FDA) approved VOQUEZNA® (vonoprazan) as a new treatment for the healing and maintenance of erosive esophagitis and the relief of heartburn associated with erosive esophagitis in adults. This FDA approval...
by Eric Christianson | Nov 19, 2023 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
Weight loss has been an essential area in which many pharmaceutical companies have made interventions by providing effective medications that can assist patients dealing with obesity. In this article, we will compare the newly approved weight loss medication Zepbound...
by Eric Christianson | Oct 25, 2023 | Clinical Pharmacy News and New Drug Updates, Hematology and Immunology Case Studies
The CDC has approved RSV vaccines for patients over the age of 60 and those who are pregnant. We provide an RSV vaccine comparison table below to help you recognize the differences between these vaccines and who may benefit from vaccination. RSV Vaccine Comparison...
by Eric Christianson | Aug 9, 2023 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
There’s always this voice in the back of my head that always cautions me that all that glitters is not gold. After being heralded as the next savior in weight loss by the media, the GLP-1 Agonists/GIP agonists have come under more scrutiny lately in the news. A...
by Eric Christianson | Jun 7, 2023 | Clinical Pharmacy News and New Drug Updates
A new SGLT2i is now on the market, promoting a new option for diabetes management. Bexagliflozin (Brenzavvy) got FDA approval in January of this year adding it to the list of SGLT2 inhibitors. With a few already on the scene, it bears the question, is bexagliflozin...
